Clinical trials: Oral Anticoagulant
Atrial Fibrillation (AF)
Protocol for Improvement of Therapy With Warfarin
Atrial Fibrillation (AF) is the most common supraventricular arrhythmia in clinical practice. The presence of AF, as an independent factor, increases mortality by up to two times.
- Trial name
- WARFALGORIT (NCT06789588)
- Testing
- pharmacogenetic algorithm, Clinical treatment
- Where
- Brazil
- Volunteers
- 700 people
- Sponsor
- University of Pernambuco
Pulmonary Embolism Acute, Venous Thromboembolism (VTE)
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism
This prospective, open-label, randomized controlled trial will compare clinically relevant bleeding during the first three months of treatment with apixaban versus rivaroxaban in adults with acute pulmonary embolism (PE) in a…
- Trial name
- APIX-PE (Apixa (NCT07774273)
- Testing
- Drug: Apixaban, Drug: Rivaroxaban
- Where
- Pakistan
- Volunteers
- 540 people
- Sponsor
- Combined military hospital lahore
Severe Bleeding, Urgent Surgery
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are…
- Trial name
- RADOA (NCT01722786)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Ischem Heart Disease, Primary Coronay Intervention
CHAOS Registry Study
INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart valves, or venous thromboembolism.
- Conditions
- Ischem Heart Disease, Primary Coronay Intervention, Oral Anticoagulants, Atrial Fibrillation
- Trial name
- CHAOS (NCT03558295)
- Testing
- Oral Anticoagulant
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Oral Anticoagulant Therapy
Dental Implants in Patients Under Oral Anticoagulant Therapy
This study evaluated the outcomes in the post-operative recovery following dental implant surgery in patients who continued on oral anticoagulated therapy (OAT) with warfarin.
- Trial name
- NCT04846114
- Testing
- Dental implant surgery
- Where
- Argentina
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Jorge Ernesto Aguilar
Aortic Valve Disease
DIrect Oral Anticoagulation and Bioprothesis Aortic Valve
DIAMOND study is a national, multicentre, randomized, parallel-group, open label study in patients (aged ≥18 years) with aortic bioprosthesis (excluding TAVI) at least 7 days after cardiac surgery.
- Trial name
- DIAMOND (NCT05687448)
- Testing
- Apixaban 5 MG Oral Tablet, Aspirin 75 to 100mg once a day
- Where
- France
- Volunteers
- 1,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Under Oral Anticoagulation Patients
Evaluation of the Contribution of a Pre-consultation Questionnaire on the Therapeutic Education
To assess the value of a dedicated knowledge questionnaire, filled by the patient prior consultation. Indeed, it could allow to target specific shortcomings of patients first, and help the cardiologist to prioritize the other…
- Trial name
- EDUCONSULT (NCT02907151)
- Testing
- Survey
- Where
- France
- Volunteers
- 160 people
- Sponsor
- University Hospital, Montpellier
Anticoagulants; Increased, Left Ventricular Thrombosis
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
Left ventricular (LV) thrombus is a common problem that is encountered in patients who survived from a large myocardial infarction, and distal systemic embolization is the main issue in these patients due to its major clinical…
- Trial name
- No-LVT (NCT03926780)
- Testing
- Rivaroxaban 20 MG, Warfarin Sodium
- Where
- Egypt
- Volunteers
- 79 people
- Sponsor
- The Young Investigator Group of Cardiovascular Research
Non Valvular Atrial Fibrillation (nv AF)
Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
"The aim of the study is to compare, in real life, the risk benefit (including both major bleeding and thrombotic events (TE) and death from any cause) associated with direct oral anticoagulants (DOAC) and with anti vitamin K…
- Trial name
- Presage-Aco (NCT02906527)
- Testing
- Non-exposed group, Exposed group
- Volunteers
- 150,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Intracerebral Hemorrhage
rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets
Evaluation of efficacy and safety of recombinant factor VIIa versus standard therapy in preventing early haematoma growth in spontaneous acute intracerebral haemorrhage in patients treated with oral anticoagulants or…
- Trial name
- NCT00222625
- Testing
- rFVIIa + (vit K in AO patients), FFP or aPCC+ vit K in AO treated patients
- Where
- 9 sites in Italy
- Volunteers
- 32 people
- Sponsor
- University Of Perugia
Venous Thromboembolism
REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.
Patients with unprovoked venous thromboembolism (VTE) or VTE associated with persistent risk factors have a high risk of recurrence after stopping anticoagulation.
- Trial name
- RENOVE (NCT03285438)
- Testing
- Reduced dose of DOAC, Full dose of DOAC
- Where
- 39 sites in France
- Volunteers
- 2,774 people
- Sponsor
- University Hospital, Brest
Atrial Fibrillation
Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years
The objective of this study was to investigate whether there is a link between clinical and biological variables and bioassay high xaban in elderly patients as part of an unscheduled hospitalization.
- Trial name
- AOD-SA (NCT02894450)
- Testing
- blood test
- Where
- France
- Volunteers
- 70 people
- Sponsor
- Nantes University Hospital
Healthy Volunteers
A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers
The purpose of this study is to evaluate the safety, tolerability and Pharmacokinetics/Pharmacodynamics of multiple doses of GCC-4401C in healthy male subjects.
- Trial name
- NCT01954238
- Testing
- GCC-4401C, Rivaroxaban
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Covid19, Venous Thromboembolism
Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial
The Michelle trial is expected to provide high-quality evidence around the role of extended thromboprophylaxis in COVID-19 and will help guide medical decisions in clinical practice.
- Trial name
- MICHELLE (NCT04662684)
- Testing
- Rivaroxaban 10 MG
- Where
- Brazil
- Volunteers
- 320 people
- Sponsor
- Science Valley Research Institute
Atrial Fibrillation
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A study for patients with abnormal heart rhythm (atrial fibrillation) who need to undergo cardioversion (procedure to restore normal heart rhythm).
- Trial name
- X-VERT (NCT01674647)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Vitamin K antagonist (VKA)
- Where
- 178 sites in United States, Belgium and 15 more
- Volunteers
- 1,504 people
- Sponsor
- Bayer
Healthy Volunteers
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
- Trial name
- DRIVING (NCT01627665)
- Testing
- D->R->C+R, D->R->C+D, R->D->C+D
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma, Leukemia
Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies
This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological…
- Conditions
- Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma, Venous Thromboembolic Disease
- Trial name
- HEM-DOAC (NCT07270263)
- Testing
- Apixaban, Rivaroxaban, low molecular weight heparin (enoxaparin sodium)
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Gdansk
Auricular Fibrillation, Anticoagulant Drugs
Discontinuation for Oral Anticoagulants in Patients With Atrial Fibrillation
The purpose of this study is to compare the discontinuation rates for vitamin K antagonists and for direct oral anticoagulants during their first year
- Trial name
- NCT04133545
- Where
- Argentina
- Volunteers
- 360 people
- Sponsor
- Hospital Italiano de Buenos Aires
Venous Thromboembolism
Impact of Early Debriefing and Enhanced Educative Components on Direct Oral Anticoagulant Adherence After Venous Thromboembolism.
Venous thromboembolism (VTE) is a frequent multifactorial and potential life-threatening disease. Once VTE has been diagnosed, anticoagulation should be started and prolonged for at least three to six months in order to reduce…
- Trial name
- DEBRIEF-VTE (NCT04141254)
- Testing
- Debriefing and educative components, Without debriefing and educative components
- Where
- 10 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest